This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The mean age was 67.3 (+/-6) years in the MS group and 66.3 (+/-6.7) years in the VATS group. The proportion of men was 57% in both groups.
Study design
Two main comparisons were made. These corresponded to two different study designs, a randomised, clinical trial and a prospective cohort study. Eight centres performed LVRS by MS only and 3 centres by VARS only. Six centres performed both VATS and MS. In the non-randomised comparison, the pooled MS group (data from 14 centres) was compared with the pooled VATS group (data from 9 centres). In the randomised comparison, the MS and VATS groups at the 6 centres were compared; there were 77 patients in the MS group and 71 patients in the VATS group. The method of randomisation was not described. It was not stated whether blinding was performed. The average length of follow-up was 31.9 months. Details of the loss to follow-up were not reported.
Analysis of effectiveness
The effectiveness results were based on all patients included in the initial study sample. The outcome measures used were: the mortality rates;
intra-operative outcomes, including blood loss, need for transfusion, operating time, and complications; days in intensive care unit (ICU) and days on mechanical ventilation; the length of stay (LOS); the proportion of patients living independently after the operation; and functional outcomes, including exercise capacity, FEV1, 6-minute walk distance, St George's Respiratory questionnaire, and Quality of Well-Being Scale after 12 and 24 months of follow-up.
The study groups were comparable in terms of the demographic and disease characteristics. However, there was a larger proportion of patients with heterogeneous emphysema in the MS group compared with the VATS group (61% versus 51%, p=0.04). When the analysis was restricted to the randomised group, the patients were comparable on all aspects.
Effectiveness results
Data were presented for the non-randomised comparison, while p-values were reported for the whole study (both nonrandomised and randomised patients).
There were no intra-operative deaths in either treatment group. The 30-day mortality rate was 2.8% for MS and 2% for VATS, (p=0.76). The 90-day mortality rate was 5.9% for MS and 4.6% for VATS, (p=0.67). The overall mortality rate over the follow-up period was 0.08 deaths per person-year for MS patients and 0.10 deaths per person-year for VATS patients (risk ratio for death in the VATS group, 1.18; p=0.42). Similar results were observed in the randomised comparison.
There were no statistically significant differences in blood loss, (p=0.55), and the need for transfusion, (p=0.99). However, the operating time was 105 minutes with MS and 126.7 minutes with VATS, (p<0.001).
Ninety-three per cent of MS patients and 86.2% of VATS patients had no intra-operative complications, (p=0.02). However, hypoxemia was the only intra-operative complication significantly less frequent with MS than with VATS (0.8% versus 5.3%; p=0.004).
During the 30 days after operation, the only statistically significant different complication was the need to reoperate for air leak (2.2% with MS versus 5.9% with VATS; p=0.05). However, in the randomised comparison, only the failure to wean differed significantly (7.8% with MS versus 0% with VATS; p=0.03).
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There was no difference in the number of days with air leak in the two groups.
In general, patients in the MS group required more ICU days than those in the VATS group, (p<0.001). The difference did not reach statistical significance in the randomised comparison. The need for mechanical ventilation was comparable.
LOS data were available for 343 MS patients and 146 VATS patients. The mean LOS was 17 (+/-19) days for MS patients and 14 (+/-9) days for VATS patients, (p=0.06). The median LOS was 10 days for MS patients and 9 days for VATS patients, (p=0.01). The LOS was significantly shorter for VATS patients in the randomised comparison.
The proportions of patients living independently were 70.5% with MS and 80.9% with VATS after 30 days, (p=0.02), and 87.5% (MS) versus 90.8% VATS) after 4 months, (p=0.36). Similar results were obtained in the randomised comparison.
Functional outcomes were comparable between the two groups in both the non-randomised and the randomised comparisons.
Clinical conclusions
The effectiveness analysis showed that functional outcomes and mortality data were comparable between the groups. A shorter LOS was observed with VATS. With respect to the frequency of complications, hypoxemia was significantly less frequent with MS, while significantly more VATS patients required reoperation for air leak.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
Discounting was not relevant since the costs were incurred during a 6-month period. The unit costs were not presented separately from the quantities of resources used, and a breakdown of the cost items was not provided. The economic evaluation included hospital and physician costs, as well as all medical and non-medical costs incurred over the 6-month postoperative period. The cost/resource boundary of the third-party payer appears to have been adopted. Resource use and costs were estimated using Medicare data that were available for 343 MS patients and 146 VATS patients. The price year was not reported.
Statistical analysis of costs
The mean costs were estimated using the non-parametric Kaplan-Meier sample average estimator, then compared using 2-sample t-tests. The median costs were compared using the Wilcoxon rank sum test.
